Biotech
Aliada Therapeutics
Aliada Therapeutics raises $1.4B Acquisition at $1.4B valuation
$1.4B
Total Raised
Acquisition
Latest Round
2018
Founded
90+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$1.4B
Latest Round Size
$1.4B
Latest Round Date
October 2024
Aliada Therapeutics: Acquisition Funding Round
Aliada Therapeutics has successfully raised $1.4B in Acquisition funding, reaching a valuation of $1.4B.
Company Overview
Blood-brain barrier platform acquired by AbbVie for CNS therapies
Funding Details
The Acquisition round was led by AbbVie (acquirer).
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Aliada Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- AbbVie (acquirer): Verified investor in Acquisition
Key Investors
AbbVie (acquirer)
Lead Investor
Verified investor in Acquisition
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M